Clinical Trials Browser

Phase 2 × INDUSTRY × 1 year × Clear all

NCT02365597 2026-03-19

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT04083976 2026-03-19

RAGNAR

Phase 2 Active not recruiting

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

NCT06040099 2026-03-19

EMERALD-Y90

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06246643 2026-03-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Phase 2 Active not recruiting

Solid Malignant Tumors

NCT06708455 2026-03-19

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Phase 2 Not yet recruiting

Melanoma

NCT06780098 2026-03-19

MK-3475-01I

Phase 2 Recruiting

Lung Neoplasms

NCT06995677 2026-03-19

SURF302

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07225621 2026-03-19

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT07326566 2026-03-19

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 2 FDA

Lymphoma, Mantle-Cell

NCT04814108 2026-03-18

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Phase 2 Completed

Cystadenocarcinoma, Serous

NCT05217446 2026-03-18

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05635708 2026-03-18

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05702229 2026-03-18

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05962606 2026-03-18

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Phase 2 Completed

Community-Acquired Pneumonia, Lymphoma, Follicular, Pneumonia

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07071714 2026-03-18

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07481058 2026-03-18

A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02467270 2026-03-17

OPTIC

Phase 2 Completed

283 enrolled 31 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT04133636 2026-03-17

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04484142 2026-03-17

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04486378 2026-03-17

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06157892 2026-03-17

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06581432 2026-03-17

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Phase 2 Recruiting

Other solid neoplasm

Solid Tumours

NCT06992258 2026-03-17

FRUITION

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07155174 2026-03-17

SEZanne

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07332000 2026-03-17

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07475806 2026-03-17

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07476287 2026-03-17

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, B-Cell

NCT03485209 2026-03-16

innovaTV 207

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT04728893 2026-03-16

MK-1026-003

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT05114746 2026-03-16

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05848011 2026-03-16

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05907954 2026-03-16

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2 Active not recruiting

Uveal Melanoma, Plaque, Amyloid

NCT06003231 2026-03-16

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Phase 2 Active not recruiting

GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06332092 2026-03-16

HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06667908 2026-03-16

CONVERGE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06987539 2026-03-16

THYME

Phase 2 Recruiting

Myasthenia Gravis